Clinical  	Clinical  	 JJ	B-NP
relevance  	relevance  	 NN	I-NP
of  	of  	 IN	I-NP
monoclonal  	monoclonal  	 JJ	I-NP
antibodies  	antibodies  	 NNS	I-NP
in  	in  	 IN	O
non  	non  	 JJ	B-NP
small  	small  	 JJ	I-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
Targeted  	Targeted  	 NNP	I-NP
therapies  	therapies  	 NNS	I-NP
with  	with  	 IN	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
improve  	improve  	 VB	O
the  	the  	 DT	O
outcome  	outcome  	 NN	O
of  	of  	 IN	O
non-small  	non-small  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
NSCLC 	NSCLC 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Current  	Current  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
focus  	focus  	 VBP	O
on  	on  	 IN	O
the  	the  	 DT	O
blockade  	blockade  	 NN	O
of  	of  	 IN	O
growth  	growth  	 NN	B-NP
factor  	factor  	 NN	I-NP
receptors  	receptors  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
inhibition  	inhibition  	 NN	O
of  	of  	 IN	O
angiogenesis 	angiogenesis 	 NN	B-NP
.  	.  	 .	O
Epidermal  	Epidermal  	 JJ	B-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
receptor  	receptor  	 NN	I-NP
( 	( 	 -LRB-	O
EGFR 	EGFR 	 NNP	B-NP
) 	) 	 -RRB-	O
-directed  	-directed  	 JJ	O
monoclonal  	monoclonal  	 JJ	O
antibodies  	antibodies  	 NNS	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
platinum-based  	platinum-based  	 JJ	O
first-line  	first-line  	 JJ	B-NP
chemotherapy  	chemotherapy  	 NNS	I-NP
have  	have  	 VBP	O
shown  	shown  	 VBN	O
promising  	promising  	 JJ	O
efficacy  	efficacy  	 NN	O
in  	in  	 IN	O
phase  	phase  	 NN	O
II  	II  	 NNP	O
trials 	trials 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
a  	a  	 DT	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
trial 	trial 	 NN	O
,  	,  	 ,	O
cetuximab  	cetuximab  	 VBD	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
cisplatin 	cisplatin 	 CD	B-NP
/  	/  	 CD	O
vinorelbine  	vinorelbine  	 NNS	B-NP
resulted  	resulted  	 VBD	O
in  	in  	 IN	O
superior  	superior  	 JJ	O
survival  	survival  	 NN	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
chemotherapy  	chemotherapy  	 VB	O
alone  	alone  	 RB	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
advanced  	advanced  	 JJ	O
EGFR-positive  	EGFR-positive  	 JJ	B-NP
NSCLC 	NSCLC 	 NNP	I-NP
.  	.  	 .	O
Inhibition  	Inhibition  	 NNP	O
of  	of  	 IN	O
angiogenesis  	angiogenesis  	 NN	B-NP
has  	has  	 VBZ	O
also  	also  	 RB	O
been  	been  	 VBN	O
successfully  	successfully  	 RB	O
applied  	applied  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
new  	new  	 JJ	O
treatment  	treatment  	 NN	B-NP
strategy 	strategy 	 NN	I-NP
.  	.  	 .	O
Bevacizumab  	Bevacizumab  	 NNP	B-NP
added  	added  	 VBD	O
to  	to  	 TO	O
palliative  	palliative  	 VB	O
chemotherapy  	chemotherapy  	 NN	O
has  	has  	 VBZ	O
improved  	improved  	 VBN	B-NP
progression-free  	progression-free  	 JJ	I-NP
survival  	survival  	 NN	I-NP
in  	in  	 IN	O
two  	two  	 CD	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
trials  	trials  	 NNS	O
and  	and  	 CC	O
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
in  	in  	 IN	O
one  	one  	 CD	O
of  	of  	 IN	O
these  	these  	 DT	O
trials  	trials  	 NNS	O
in  	in  	 IN	O
selected  	selected  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
advanced  	advanced  	 JJ	O
non-squamous  	non-squamous  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer 	cancer 	 NN	I-NP
.  	.  	 .	O
Bevacizumab  	Bevacizumab  	 NNP	B-NP
is  	is  	 VBZ	O
now  	now  	 RB	O
approved  	approved  	 VBN	O
for  	for  	 IN	O
selected  	selected  	 JJ	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
advanced  	advanced  	 JJ	O
NSCLC  	NSCLC  	 NN	B-NP
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
platinum-based  	platinum-based  	 JJ	O
chemotherapy 	chemotherapy 	 NN	O
.  	.  	 .	O
Figitumumab  	Figitumumab  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
monoclonal  	monoclonal  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
against  	against  	 IN	O
the  	the  	 DT	O
insulin-like  	insulin-like  	 JJ	B-NP
growth  	growth  	 NN	I-NP
factor-1  	factor-1  	 CD	I-NP
receptor  	receptor  	 NN	I-NP
( 	( 	 -LRB-	O
IGF-1R 	IGF-1R 	 NNP	B-NP
)  	)  	 -RRB-	O
which  	which  	 WDT	O
demonstrated  	demonstrated  	 VBD	O
activity  	activity  	 NN	O
in  	in  	 IN	O
preclinical  	preclinical  	 JJ	B-NP
models  	models  	 NNS	I-NP
of  	of  	 IN	I-NP
NSCLC  	NSCLC  	 NNP	I-NP
and  	and  	 CC	O
in  	in  	 IN	O
a  	a  	 DT	O
phase  	phase  	 NN	O
II  	II  	 NNP	O
trial 	trial 	 NN	O
.  	.  	 .	O
Because  	Because  	 IN	O
of  	of  	 IN	O
these  	these  	 DT	O
promising  	promising  	 JJ	O
results 	results 	 NNS	O
,  	,  	 ,	O
three  	three  	 CD	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
open-label 	open-label 	 NNP	B-NP
,  	,  	 ,	O
international  	international  	 JJ	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
trials  	trials  	 NNS	O
of  	of  	 IN	O
figitumumab  	figitumumab  	 NN	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
locally  	locally  	 RB	O
advanced  	advanced  	 VBN	O
or  	or  	 CC	O
metastatic  	metastatic  	 JJ	B-NP
NSCLC  	NSCLC  	 NNS	I-NP
are  	are  	 VBP	O
in  	in  	 IN	O
progress 	progress 	 NN	O
.  	.  	 .	O
